Feline immunodeficiency virus (FIV)-induced immunodeficiency disease in domestic cats represents an important veterinary health problem and serves also as a very useful small-animal model for AIDS antiviral therapy and vaccine development (2, 4, 7) . The virus is transmitted by blood and saliva; about 1 to 6% of cats worldwide are infected (5, 10, 18) . We reported that over 90% of cats immunized with either inactivated infected-cell or inactivated cell-free whole-FIV vaccines were protected against experimental infection with homologous and heterologous strains of FIV (19, 20) . Protection appeared to correlate with vaccine induction of strong antiviral immune responses including high-titered neutralizing antibodies. In contrast to the observed protection against simian immunodeficiency virus (SIV) by the infected human T cells used to grow the virus (14) , immunization with analogous uninfected feline T cells did not protect cats against challenge infection with FIV grown in the same cells (20) . However, anticellular antibodies did add a nonspecific adjuvant effect to the vaccines (20) . To further determine the mechanism of FIV vaccine protection, we evaluated the role of antiviral and anticellular antibodies by passive immunization against experimental FIV infection.
Eighteen specific-pathogen-free (SPF) cats, 3 to 6 months of age, were divided into three study groups as shown in Table 1 . In the first study, three cats were passively immunized with pooled sera from vaccinated cats and three control cats received phosphate-buffered saline (PBS) or pooled control cat sera. The vaccine serum pool was from nine unchallenged SPF cats that had been immunized three times at 3-to 4-week intervals with inactivated FIV vaccines, consisting of either fixed infected allogeneic T cells (FL-4 cells) or semi-purified cell-free virus harvested from the same cells; both vaccines were mixed in threonyl muramyl dipeptide (SAF-1) adjuvant (250 ,ug per dose), as described previously (19) . This vaccination protocol previ-* Corresponding author.
ously protected cat against intraperitoneal (i.p.) infection with a low dose of homologous cell-free FIV (Petaluma strain) (19, 20) . The FIV-neutralizing (VN) titer of this pooled serum was 1,280. The control serum pool, from nine SPF cats which were either unimmunized or immunized with adjuvant only, had no VN titer.
In the second study, two groups of three cats each were passively immunized with pooled sera from either six experimentally FIV-infected or six control SPF cats. Any live virus in the pooled sera, collected from cats at 9 to 10 months postinfection with 10 50% animal infectious doses (10 ID50) of FIV Petaluma, was inactivated by a combination of heat (56°C for 40 min) and HCl (pH 4 for 2 h) treatment, a method previously reported to completely inactivate human immunodeficiency virus type 1 (HIV-1) in infected human sera (9, 16) . The pooled control serum was similarly treated. The VN titer of the pretreated pooled serum from the infected cats was about 2,560, and that of control sera was <8 (below the detectable level). The heat and acid pretreatment did not lower the VN titer.
In the third study, two SPF cats each were passively immunized with either pooled sera from two assay (19) and for infectious virus by virus isolation (19, 20) . One cat was passively immunized with inactivated sera from infected cats and monitored for FIV infection as a control to determine whether any residual viable virus remained after the heat and acid treatment. Passive immunization with vaccine sera (study 1) . High titers of anti-transmembrane peptide (anti-TM) (Fig. 1A) , (titer, VN 64 to 128) (Fig. 1B) , and anti-p25 (titer, 1:10,000 to 1:50,000) (data not shown) antibodies were detected at 1 week after challenge, 8 days after the first passive immunization, in cats passively immunized with vaccine sera. In all three cats, titers of viral antibody derived from passive immunization gradually decreased and were undetectable by 16 to 19 weeks p.c. (Fig. 1) . At 19 weeks p.c., FIV infection was undetectable in the cats by virus isolation ( Table 1) . The lack of an antibody response to virus challenge ( Fig. 1 ) and the lack of isolatable virus indicated that all three cats passively immunized with vaccine sera were protected from homologous FIV challenge. In contrast, the three control cats developed anti-p25 antibody titers (from 1:100 at 6 weeks p.c to 1:10,000 at 19 weeks p.c.; data not shown), anti-TM antibody titers (Fig. 1A) , and VN antibody titers (Fig. 1B) (Table 1) .
Passive immunization with infected sera (study 2). Significant titers of anti-TM ( Fig. 2A) , VN (128 to 256) (Fig. 2B) , and anti-p25 (1:5,000 to 1:20,000) (data not shown) antibodies were detected at 1 week p.c. in all four cats passively immunized with inactivated sera from infected cats. In both challenged and unchallenged cats, the FIV antibody titers steadily declined and after 9 weeks p.c., the antibodies were no longer detectable (Fig. 2) . In contrast, starting 7 weeks p.c., the three cats passively immunized with pretreated control sera developed significant titers of anti-p25 (data not shown) and anti-TM ( Fig. 2A) well) with bicarbonate buffer (pH 9.6), incubated overnight at 37°C, and washed once with washing buffer before being used (19) .
Absorption of pooled vaccine sera (study 1) with fixed uninfected cells (FeTl and 3201) did not significantly lower the VN titer (1,280 to 640), whereas absorption with an identical number of fixed FIV-infected FL-4 cells completely removed the VN titer (<8) ( Table 2 ). The titer of anti-FeTl antibody remaining in the FL-4-absorbed sera was similar to the titer of antibody remaining in sera absorbed with unin- WEEKS POST-CHALLENGE 1, 280) in infected sera (from study 2) was observed upon absorption with uninfected cells. This decrease was probably due to nonspecific attachment and to dilution from the traces of PBS still remaining in the pelleted fixed cells used for absorption. Thus, the VN titer of the sera from cats immunized with either fixed infected-cell or inactivated whole-virus vaccine was unaffected by absorption with the uninfected cells used to grow the virus. Similarly, absorption with FeLV-infected feline T cells (FL-74 line) did not affect the VN titers.
Cats passively immunized the sera from either FIV-vaccinated or FIV-infected cats were protected from FIV infection at an i.p. challenge dose (5 ID50) which infected all control cats. High titers of anticellular antibodies were detected in the vaccine sera, but no such antibodies were present in the infected sera used for immunization. Moreover, these antibodies could not be the critical correlate for vaccine protection because passive immunization of cats with sera containing only high titers of anticellular antibodies did not protect these animals from FIV challenge. Furthermore, we previously showed that cats immunized with the uninfected allogeneic T cells used to grow the vaccine virus were not protected against i.p. challenge infection (20) . Thus, in contrast to immune protection elicited in macaques by inactivated SIV-infected-cell or cell-free virus vaccines (1, 14) , anticelluar antibodies do not appear to be critical to the passive antibody protection observed in the current studies. However, our previous results with inactivated Pretreated (heat-and pH 4-inactivated) infected sera used in study 2.
f Pooled vaccine sera from cats immunized with uninfected feline T cells (FeTl and 3201 cells) . These are the anti-FeTl and anti-3201 cell sera used in study 3. whole-virus vaccines suggest that anticellular antibodies exert an adjuvant effect to the vaccine immunogenicity (20) .
In Sweden, passive protection with sera from SIV-infected and HIV-2-vaccinated monkeys has also been reported. Three of four monkeys passively immunized (9 ml/kg of body weight) with inactivated pooled sera with high VN titers from monkeys infected with SIVam were protected against 10-to 100-ID50 homologous challenges given 5 h after immunization (12) . Protection of two of three cynomolgus monkeys was obtained with sera (9 ml/kg) (VN titer, 2,560) from a monkey given an HIV-2 vaccine 6 h before intravenous challenge with 10 ID50 of HIV-2 (12). The virus for the vaccine was grown in human cells, while the virus for the challenge was passaged twice in human peripheral blood lymphocytes and subsequently twice in monkey peripheral blood lymphocytes. Both of these studies suggested that high titers of virus-specific antibodies were required for protection (12) . However, passive immunization results at the University of California, Davis, have indicated a stronger correlation of anticellular antibodies than of antiviral antibodies to protection against infection with SIVmac (13). Therefore, in the SIV macaque model, the relative importance of anticellular antibodies compared with antiviral antibodies in the protective immunity elicited by the inactivated whole-virus vaccine remains unclear.
In the FIV cat system, the picture appears to be clearer in that passive antibody protection may be mediated primarily by VN antibodies. The vaccine serum pool used for passive immunization had a VN titer of 1,280, and the recipient cats had VN titers of 64 to 128 at 8 days after the first transfer. A slightly higher VN titer of 2,560 was detected in the infectedcat sera used for passive immunization, and the recipients of these sera had VN titers of 128 to 256 at 8 days after the first immunization. In contrast, cats immunized with uninfectedcell or control sera which had no VN titer were unprotected against FIV infection. Whereas protected cats immunized with inactivated whole-virus vaccine had an average VN titer of 100 at the time of FIV challenge (19) , immunized cats with lower VN titers were unprotected from low-dose virus challenge (10 to 20 ID50) (7) . It seems unlikely that virusinfected FL-4 cells and virus derived from them induced a more vigorous or qualitatively different anticell response than the uninfected FeTl counterpart because the titers of anticellular antibodies were similar in cats immunized with infected fixed feline T cells and in those immunized with uninfected T cells ( Table 2) .
These passive protection results demonstrate that protection observed in cats with active immunization (19, 20) 
